Tied with Cabenuva for second place was Amgen’s Lumakras, which was approved in 2021 for non-small cell lung cancer and boasted impressive therapeutic and R&D scores, but fell behind both ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...

Issued on behalf of Oncolytics Biotech Inc. At the ASCO GI event, Oncolytics shared that in relapsed anal cancer, 4 out of 12 evaluable patients achieved a partial response for a response rate of ...

In January and February of this year, the US Food and Drug Administration granted approvals for Adcetris (brentuximab vedotin), Lumakras (sotorasib), Grafapex (treosulfan), Enhertu (fam ...

This design is broader than the currently approved KRAS inhibitors, Amgen's Lumakras (sotorasib) and Bristol Myers Squibb's Krazati (adagrasib), which target only the "off" state of KRAS G12C. "While ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a cell’s DNA, can help doctors understand how cancer might grow and ...

KRAS G12C inhibitors like sotorasib (Lumakras) and adagrasib (Krazati) have been effective for some patients whose cancers harbor this mutation, but many patients' cancers are resistant to therapy ...

Removable grinding wheel Cup selector for 2-12 cups Finess selector Discover the perfect grind with the De'Longhi 120g Burr Coffee Grinder, designed to enhance your coffee experience. Its innovative ...